Antipyretic effect of cycloheximide, and inhibitor of protein synthesis, in patients with Hodgkin's disease or other malignant neoplasms.
Infusion of cycloheximide i.v., an antibiotic known to inhibit synthesis of protein, at a rate of 0.2 mg/kg/hr, reliably caused lysis of fever in 15 chronically febrile patients with Hodgkin's disease who did not have detectable bacterial, fungal, or viral infection. Antipyretic effects were also seen in some patients with reticulum cell sarcoma, lymphosarcoma, acute leukemia, histiocytic medullary reticulosis, plasma cell myeloma, carcinoma of the lung, and carcinoma of the cervix. The drug failed to produce defervescence in four patients with normal granulocyte reserves, who were febrile due to bacterial infection. When infused at a rate of 0.2 mg/kg/hr, the drug apparently caused an acute alteration of protein metabolism in man in that plasma amino acid nitrogen rose acutely while plasma levels of muramidase and ribonuclease fell during the period of the infusion. The data suggest that continuing synthesis of protein may be involved in nonbacterial fever of neoplastic disease. Mammalian granulocytes and monocytes are known to elaborate a pyrogenic protein following appropriate stimulation; it is suggested that in some types of neoplastic disease, particularly Hodgkin's disease, tumor cells may produce and release a pyrogenic protein and that drug-induced inhibition of its synthesis is responsible for the observed lysis of fever.
D001424:Bacterial Infections / Q000150:complications; D003513:Cycloheximide / Q000627:therapeutic use*; D005260:Female; D005334:Fever / Q000188:drug therapy* / Q000209:etiology; D006689:Hodgkin Disease / Q000150:complications* / Q000201:enzymology; D006801:Humans; D007938:Leukemia / Q000150:complications; D008175:Lung Neoplasms / Q000150:complications; D008206:Lymphatic Diseases / Q000150:complications; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D009101:Multiple Myeloma / Q000150:complications; D009113:Muramidase / Q000097:blood; D009363:Neoplasm Proteins / Q000096:biosynthesis; D009369:Neoplasms / Q000188:drug therapy*; D009584:Nitrogen / Q000097:blood; D012260:Ribonucleases / Q000378:metabolism; D002583:Uterine Cervical Neoplasms / Q000150:complications
D009363:Neoplasm Proteins; D003513:Cycloheximide; D012260:Ribonucleases; D009113:Muramidase; D009584:Nitrogen